Development of liver surface nodularity quantification program and its clinical application in nonalcoholic fatty liver disease

被引:14
|
作者
Kim, Tae-Hoon [1 ]
Kim, Ji E. On [1 ]
Ryu, Jong-Hyun [1 ]
Jeong, Chang-Won [1 ]
机构
[1] Wonkwang Univ, Med Convergence Res Ctr, Iksan 54538, South Korea
基金
新加坡国家研究基金会;
关键词
QUANTITATIVE IMAGING BIOMARKERS; FIBROSIS; ELASTOGRAPHY; COMPLICATIONS; EPIDEMIOLOGY; PERFORMANCE; DIAGNOSIS; CIRRHOSIS; ACCURACY; FEATURES;
D O I
10.1038/s41598-019-46442-y
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The liver morphological changes in relation to fibrosis stage in nonalcoholic fatty liver disease (NAFLD) have not yet been clearly understood. This study was to develop a liver surface nodularity (LSN) quantification program and to compare the fibrosis grades in simple steatosis (SS) and nonalcoholic steatohepatitis (NASH). Thirty subjects (7 normal controls [NC], 12 SS and 11 NASH) were studied. LSN quantification procedure was bias correction, boundary detection, segmentation and LSN measurement. LSN scores among three groups and fibrosis grades compared using Kruskal-Wallis H test. Diagnostic accuracy was determined by calculating the area under the receiver operating characteristics (ROC) curve. Mean LSN scores were NC 1.30 +/- 0.09, SS 1.54 +/- 0.21 and NASH 1.59 +/- 0.23 (p = 0.008). Mean LSN scores according to fibrosis grade (F) were F0 1.30 +/- 0.09, F1 1.45 +/- 0.17 and F2&F3 1.67 +/- 0.20 (p = 0.001). The mean LSN score in F2&F3 is significantly higher than that in F1 (p = 0.019). The AUROC curve to distinguish F1 and F2&F3 was 0.788 (95% CI 0.595-0.981, p = 0.019) at a cut-off LSN score greater than 1.48, and its diagnostic accuracy had 0.833 sensitivity and 0.727 specificity. This study developed LSN program and its clinical application demonstrated that the quantitative LSN scores can help to differentially diagnose fibrosis stage in NAFLD.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Obesity and the liver: nonalcoholic fatty liver disease
    Koppe, Sean W. P.
    TRANSLATIONAL RESEARCH, 2014, 164 (04) : 312 - 322
  • [32] Nonalcoholic fatty liver disease
    Madan, P
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2005, 173 (07) : 734 - 735
  • [33] Nonalcoholic fatty liver disease
    Brunt, Elizabeth M.
    Wong, Vincent W. -S.
    Nobili, Valerio
    Day, Christopher P.
    Sookoian, Silvia
    Maher, Jacquelyn J.
    Bugianesi, Elisabetta
    Sirlin, Claude B.
    Neuschwander-Tetri, BrentA.
    Rinella, Mary E.
    NATURE REVIEWS DISEASE PRIMERS, 2015, 1
  • [34] Nonalcoholic Fatty Liver Disease
    Filipovic, Branka
    Forbes, Alastair
    Tepes, Bojan
    Dumitrascu, Dan L.
    CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 2018
  • [35] Nonalcoholic Fatty Liver Disease: Its Mechanisms and Complications
    El Ouaamari, Abdelfattah
    Minehira, Kaori
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2013, 2013
  • [36] Nonalcoholic fatty liver disease
    Bebawi, Emmanuel
    Takla, Mark
    Leonard, Jennifer
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2023, 195 (26) : E909 - E909
  • [37] Nonalcoholic fatty liver disease
    Lemoine, Maud
    Serfaty, Lawrence
    PRESSE MEDICALE, 2012, 41 (02): : 169 - 189
  • [38] Nonalcoholic Fatty Liver Disease
    Worm, N.
    Stein, J.
    Strohle, A.
    DIABETES STOFFWECHSEL UND HERZ, 2016, 25 (02): : 85 - 94
  • [39] Nonalcoholic fatty liver disease and liver transplantation
    Angulo, P
    LIVER TRANSPLANTATION, 2006, 12 (04) : 523 - 534
  • [40] Nonalcoholic fatty liver disease
    Mach, Tomasz
    PRZEGLAD GASTROENTEROLOGICZNY, 2007, 2 (02): : 101 - 105